Top-line data for Sanofi SA and Regeneron Pharmaceuticals Inc.'s phase II trial of the IL-33 antibody REGN-3500 show patients with moderate to severe asthma treated with Dupixent (dupilumab) monotherapy did numerically better than REGN-3500 across all endpoints. And combining REGN-3500 and Dupixent did not demonstrate increased benefit compared to Dupixent monotherapy.